Evidence mapPaperPMID 39689849Full record

Trial reportEuropean heart journal2025

Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial.

Inés Domínguez-López, Rosa M Lamuela-Raventós, Cristina Razquin, Camila Arancibia-Riveros, Polina Galkina, Jordi Salas-Salvadó, Ángel M Alonso-Gómez, Montserrat Fitó, Miquel Fiol, José Lapetra and 10 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Inés Domínguez-LópezPolyphenol Research Group, Departament de Nutrició, Ciències de l'Alimentació i Gastronomía, Facultat de Farmacia, Universitat de Barcelona (UB), Av. de Joan XXII, 27-31, Barcelona 08028, Spain.
Rosa M Lamuela-RaventósPolyphenol Research Group, Departament de Nutrició, Ciències de l'Alimentació i Gastronomía, Facultat de Farmacia, Universitat de Barcelona (UB), Av. de Joan XXII, 27-31, Barcelona 08028, Spain.
Cristina RazquinCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Camila Arancibia-RiverosPolyphenol Research Group, Departament de Nutrició, Ciències de l'Alimentació i Gastronomía, Facultat de Farmacia, Universitat de Barcelona (UB), Av. de Joan XXII, 27-31, Barcelona 08028, Spain.
Polina GalkinaPolyphenol Research Group, Departament de Nutrició, Ciències de l'Alimentació i Gastronomía, Facultat de Farmacia, Universitat de Barcelona (UB), Av. de Joan XXII, 27-31, Barcelona 08028, Spain.
Jordi Salas-SalvadóCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.ORCID 0000-0003-2700-7459
Ángel M Alonso-GómezCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Montserrat FitóCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Miquel FiolCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.ORCID 0000-0002-5370-1391
José LapetraCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Enrique Gómez-GraciaDepartment of Preventive Medicine, University of Malaga, Malaga, Spain.
José V SorlíDepartment of Preventive Medicine, University of Valencia, Spain.ORCID 0000-0002-0130-2006
Miguel Ruiz-CanelaCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.ORCID 0000-0002-7684-2787
Olga CastañerCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Liming LiangDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Lluis Serra-MajemInstitute for Biomedical Research, University of Las Palmas de Gran Canaria, Las Palmas, Spain.
Frank B HuDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Emilio RosCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Miguel Ángel Martínez-GonzálezCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.
Ramon EstruchCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Monforte de Lemos 3-5, Pabellón 11, Madrid 28029, Spain.ORCID 0000-0003-1260-4445

Funding

Mediterranean diet, Metabolites, and Cardiovascular DiseaseR01HL118264 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2023 to 2025
$1.0M
AEICICYT [PID2020-114022RB-I00European Research 101097681FEDERGeneralitat de Catalunya 2017SGR 196Instituto de Salud Carlos IIIInterprofesional del vino de España-OIVE 600390Mediterranean diet, Metabolites, and Cardiovascular Disease 2R01HL118264-09 and 5R01HL118264-08MICINMinisterio de Ciencia, Innovación y UniversidadesNHLBI NIH HHS R01 HL118264NIHUE
6 · The paper itself

Abstract

BACKGROUND AND

aimsModerate wine consumption has been associated with lower cardiovascular disease (CVD) risk in older populations. However, wine consumption information through self-reports is prone to measurement errors inherent to subjective assessments. The aim of this study was to evaluate the association between urinary tartaric acid, an objective biomarker of wine consumption, and the rate of a composite clinical CVD event.

methodsA case-cohort nested study was designed within the PREDIMED trial with 1232 participants: 685 incident cases of CVD and a random subcohort of 625 participants (including 78 overlapping cases). Wine consumption was registered using validated food frequency questionnaires. Liquid chromatography-tandem mass spectrometry was used to measure urinary tartaric acid at baseline and after one year of intervention. Weighted Cox regression models were used to estimate hazard ratios (HRs) of CVD.

resultsTartaric acid was correlated with self-reported wine consumption at baseline [r = 0.46 (95% CI 0.41; 0.50)]. Five categories of post hoc urinary tartaric acid excretion were used for better representation of risk patterns. Concentrations of 3-12 and 12-35 μg/mL, which reflect ∼3-12 and 12-35 glasses/month of wine, were associated with lower CVD risk [HR 0.62 (95% CI 0.38; 1.00), P = .050 and HR 0.50 (95% CI 0.27; 0.95), P = .035, respectively]. Less significant associations between self-reported wine consumption and CVD risk were observed.

conclusionsLight-to-moderate wine consumption, measured through an objective biomarker (tartaric acid), was prospectively associated with lower CVD rate in a Mediterranean population at high cardiovascular risk.

Indexed as

BiomarkersCardiovascular DiseasesTartratesWineAgedAlcohol DrinkingFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedBiomarkerstartaric acidTartratesBiomarkerCardiovascular diseaseMediterranean dietTartaric acidWine

Identifiers

PMID39689849
PMCPMC11704392

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.